רווח למניה בשנים עשר החודשים האחרונים: synaptogen.com (SNPX)

Synaptogenix, Inc. (SNPX) automates bioinformatic analysis of brain synapses to accelerate neurodrug trials. This 12-month net income per share chart illustrates revenue dynamics, where 0.00 reflects the metric's baseline. Synaptogenix, Inc. (SNPX) is developing unique methods to combat Alzheimer's disease, although speculative capital and strict FDA oversight create high volatility within the closed patent ecosystem.

Annual net earnings per share reflect the actual return on each unit of capital, adjusted for the total number of securities. This metric allows for an objective assessment of profit generation efficiency and the timely adjustment of portfolio structure. Analyzing changes in the rolling annual EPS signals the fundamental stability of the business. This is critical for Synaptogenix, Inc. (SNPX), as the costs of temperature-controlled logistics for biosamples directly impact the bottom line. A downward trend on this chart warns of rising operating expenses.